World Mental Health Day 2022

World Mental Health Day 2022

October 10th is World Mental Health Day, aiming at shining light on the prevalence of mental ill health globally and the need to “strengthen mental health care so that the full spectrum of mental health needs is met” [1].

How common are mental illnesses?
970 million individuals worldwide, or 1 in every 8 people, had a mental illness in 2019 [2]. Due to the COVID-19 pandemic, these numbers have been even more on the rise during the past two years [1]. Anxiety and depression disorders, for example, are estimated to have increased by more than 25% among the global population during the first year of the pandemic [1].

Economic costs of mental disorders
Statistics show that in 2010, mental diseases cost the global economy US$2.5 trillion in direct and indirect costs, and mental and drug use disorders made up 10.4% of the total global illness burden [3]. By 2030, it is anticipated that the direct and indirect costs of mental illnesses will have doubled – without taking into account expenses related to mental problems that originate outside of the healthcare system, such as legal expenses brought on by the consumption of illegal drugs [3].

Stigmatization of ill mental health
More than half of those suffering from mental illness do not obtain treatment. People often put off or postpone getting therapy out of fear of being treated “differently or […] losing their jobs and livelihood” [4]. This is due to the fact that stigma, discrimination, and prejudice toward those who have mental illnesses are still major issues in today’s global society.
Often, experiencing external stigmatization can lead to greater self-stigma for individuals, which was linked to worse recovery from mental illness in scientific studies [4].

The growing treatment gap
The COVID-19 pandemic has sparked a global mental health crisis, causing millions of people to experience short- and long-term stress and jeopardizing their mental health. During COVID-19, the gap in treatment for mental health disorders has expanded significantly, while mental health services have been severely disrupted at the same time [1]. Resources in mental health services are thus limited and often not sufficient to meet the treatment needs for poor mental health [5].

What needs to change?
Mental disorders are more common than one might think, and prejudices surrounding poor mental health unfortunately only further increase the burden of the diseases on people suffering from them. It is therefore important to raise awareness about mental health problems, destigmatize mental illness, and help to ensure that individuals struggling with their mental health are not facing discrimination.
Given the high economic costs of mental disorders, it is also important to continuously work on improving the treatment support provided. Especially with lacking resources in mental health services and a growing treatment gap, this includes seeking new ways to help individuals suffering from mental health conditions.

How digital solutions for mental health can help
The use of digital platforms for remote patient monitoring and health assessment, as well as real-time patient analytics, could enable personalised treatment and improved quality of care [6]. Digital solutions for mental health could therefore offer the potential to empower and engage individuals with mental disorders to better manage their mental health, facilitating treatment for clinical professionals and empowering family caregivers to help drive down economic costs and increase productivity.
At Monsenso, we have worked with a variety of mental health disorders in both research and clinical settings. Our digital mental health solution has helped many individuals struggling with their mental health to better understand their conditions and live a more independent life, as well as helped clinicians to better support their patients. We are proud to support the World Mental Health Day and will continue to spread knowledge about mental health conditions and offer our support to individuals affected and clinicians providing treatment for mental illness.

——————————————————————————————————————————-

About Monsenso
Monsenso is a digital health company that enables better outcomes for patients and clinicians through data-driven decisions. We are focused on mental health and user-centred in designing our solutions for patients and clinicians. Our cloud-based platform is a CE-marked medical device (Class 1, pending Class 2a and MDR certification) that is HIPAA compliant, with certifications in ISO 13485, ISO 27001, Cyber Essentials and TGA. Our solution has been clinically and scientifically validated by over 70+ peer-reviewed studies and can be configured for applications across mental health conditions. We work with healthcare systems, life sciences and research organisations globally. Book a demo to learn more.

References:
[1] World Health Organization (n.d.). World Mental Health Day 2022.
https://www.who.int/campaigns/world-mental-health-day/2022

[2] World Health Organization (2022). Mental disorders.
https://www.who.int/news-room/fact-sheets/detail/mental-disorders

[3] Trautmann, S., Rehm, J. & Wittchen, H. (2016).  The economic costs of mental disorders. EMBO reports 17(9).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007565/

[4] American Psychiatric Association (n.d.). Stigma, Prejudice and Discrimination Against People with Mental Illness.
https://www.psychiatry.org/patients-families/stigma-and-discrimination#:~:text=Public%20stigma%20involves%20the%20negative,have%20about%20their%20own%20condition.

[5] Saraceno, B. (2004). Mental health: scarce resources need new paradigms. World Psychiatry 3(1): 3–5.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1414651/

[6] Elsevier Health (2022). Clinician of the Future Report 2022.
https://www.elsevier.com/connect/clinician-of-the-future

Patients will help document treatment efficacy in innovative, decentralised trials project

Patients will help document treatment efficacy in innovative, decentralised trials project

In collaboration with leading researchers and the pharmaceutical industry, the PhaseV innovation project will set new standards for how the effects of treatment can be documented so that patients are offered the right treatment. Patients and healthcare professionals will thus provide data that can help shed light on whether the treatment is working when Monsenso’s digital platform is used to support decentralised trials in the project.

To date, medical treatments have been tested primarily in long-term, randomised clinical trials to determine treatment effects and side-effects, with limited measurement of long-term effects when treatment is provided in clinical practice.

Often, drug trials take 6-15 years before a new drug can be released on the market, and 80 percent of trials fail to recruit and retain a sufficient number of patients in the trials within the set timeframe. This means that the benefits for patients and healthcare systems are often delayed. However, with digital developments, it is possible for clinics, hospitals, and patients alike to play a more active role in documenting the impact of treatments.

The new PhaseV (Phase five) innovation project, in which Innovation Fund Denmark is investing DKK 24 million (of which DKK 8,3 million goes to Monsenso), aims to develop and validate a scalable digital platform for efficient, decentralised patient recruitment, patient data collection and study execution. This is done by engaging patients and clinicians in the monitoring of treatment effects over longer periods of time based on patients’ own feedback, digital biomarkers from smartphones and wearables, as well as registry data.

With this project, we want to show that it is possible to engage and motivate patients and healthcare professionals to collect continuous data from patients over time. PhaseV will set new standards for how the efficacy and safety of new treatments can be documented in a scalable way in the future, so that patients are offered the right treatment“, says Thomas Lethenborg, CEO of Monsenso.

Digitizing the effect of patient treatments can be of decisive importance for our insight into the effects of the treatment of severely overweight people as well as for future clinical studies, where the goal is to make it easier for both patients and healthcare personnel to participate“, says Daniel Vega Møller, Vice President Medical & Science Obesity, NASH and Devices Novo Nordisk A/S.

Country Manager for Novartis in Denmark, Peter Drøidal, also sees great potential in the PhaseV project: “The healthcare system lacks resources and therefore we all need to think in new ways. This project’s combination of public and private partners offers unique opportunities to develop new digital solutions that can help improve patient care and free up personnel time“.

Severe obesity, urticaria and diabetic foot ulcers
The PhaseV project will develop a platform with three apps to collect data on patients with severe obesity, diabetic foot ulcers and urticaria – all of which are costly chronic conditions. For example, annual treatment costs for severe obesity alone are estimated to exceed DKK 15 billion for Danish municipalities and regions.

More than 800,000 Danes live with severe obesity, and associated diseases are very common. As severe obesity causes both direct and indirect costs to society, there is a significant need for good and well-documented weight loss treatments“, says Jens Meldgaard Bruun, clinical professor at Aarhus University and Steno Diabetes Center Aarhus and part of PhaseV.

Urticaria affects 15-20 percent of the population, and in about 1 percent it occurs chronically and causes a severely reduced quality of life.

Thorough monitoring and efficient data collection on symptom development are crucial for correct and effective future treatment“, says Simon Francis Thomsen, Professor and Chief Physician at Bispebjerg Hospital.

22.000 Danes live with diabetic foot ulcers and treatment costs society more than DKK 5 billion annually.

For a patient with diabetes, a foot ulcer can become critical within days, and in exceptional cases amputation may be necessary. Hence, time is of the essence, and we want to prevent serious complications“, says Klaus Kirketerp-Møller, senior physician at Bispebjerg Hospital and Steno Diabetes Center Copenhagen.

The PhaseV project is expected to bring value to patients, regions, and municipalities, as well as to the institutions and companies involved.

Attractive new market opportunity for Monsenso
“We are further developing Monsenso’s digital health platform to improve the support of decentralised trials across chronic conditions, where behaviour and ongoing follow-up play a major role in patients’ quality of life. We see both the development work and the partnerships as very interesting for Monsenso, because it opens up a new, attractive market opportunity“, says the CEO of Monsenso, Thomas Lethenborg.

The consortium behind the project, which is supported by the Innovation Fund, includes Novo Nordisk, Novartis, Aarhus University, the Research Unit for General Practice, Aarhus Municipality, Bispebjerg Hospital, the Danish Technological Institute, the Danish Life Science Cluster, Steno Diabetes Center Aarhus, the Copenhagen Institute for Future Studies and Monsenso.

Financial expectations
The project does not change Monsenso’s financial expectations for H2 2022 but is expected to contribute to increased growth in 2023 and beyond.

Facts
Innovation Fund investment: DKK 24.3 million (of which DKK 8.3 million is for Monsenso).
Total project budget: DKK 48.2 million.
Duration: 3 years
Official title: PhaseV

Further information
CEO, Monsenso
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com

Chairman of the board, Monsenso
Peter Mørch Eriksen
Tel. +45 29 00 35
E-mail: petermorcheriksen@outlook.com

Certified Adviser, Monsenso
Norden CEF A/S
John Norden
Tel. +45 20 72 02 00
E-mail: jn@nordencef.dk
——————————————————————————————————————————-

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com

 
Digitalization could help tackle the issue of lacking resources in mental health services

Digitalization could help tackle the issue of lacking resources in mental health services

Did you know that over 500.000 Danish citizens currently live with one or multiple mental health disorders [1] and that approximately half of the Danish population will suffer from a mental illness at least once in their lifetime [2]?

Mental health is declining in Denmark [2]. However, treatments and services offered to people with mental disorders often lack quality compared to those offered to people with physical disorders [2]. One of the reasons is a clear shortage of resources. 

Lack of resources as a challenge in Danish mental health services
Recruiting and retaining mental health professionals, in social psychiatry, regional psychiatry, and specialised social services focusing on children and youths [2] has been a significant struggle in recent years.

In Region South, for example, only 8 out of 21 open job positions for psychologists could be filled at the beginning of the year. In Region Zealand, it was even less: 11 applicants for 22 advertised positions, and 6 suitable candidates hired [3].

There are several assumptions for why it is so challenging to recruit mental health professionals. One of them is that we are currently experiencing a generational shift, with many healthcare professionals retiring at the same time [3].

The insufficient capacity and availability led many individuals suffering from mental illness to not receive the right treatment at the right time [2]. The average waiting time to see a psychologist in Denmark is around 16 weeks – but in many cases, patients easily wait up to 20 weeks before their first treatment [4]. 

This limited capacity also reduces the possibility of early detection and interventions. Insufficient preventive measures are a major cause of high mortality rates amongst individuals suffering from severe mental illnesses in Denmark [2].

Approaches to improve mental health services in Denmark
In order to make the quality and availability of mental health services a top priority, the Danish government decided to initiate working on a 10-year plan for the development of psychiatry in 2020, setting aside 600 million Danish Kroner annually for the improvement of mental health care in Denmark. [2].

Recommendations for the long-term plan include the expansion of easily accessible offers for mental health services in Danish municipalities (including improved offers for children and young adolescents), increased country-wide mental health promotion, and better early detection of mental illness [2]. 

None of these goals will be properly implemented if Denmark is still facing a lack of resources. But while the need to hire more trained professionals is undoubtedly critical to improve mental health services, this may also be an opportunity for scalable technologies to improve the reach of the current workforce to serve the needs of patients waiting to receive care.

Digitalization as the key to improved mental health services?
A large study by Elsevier Health (2022) shows that 77% of international clinicians expect tech companies to become “key stakeholders in managing healthcare systems in 10 years”, and that the majority of clinicians (70%) believe an increased use of digital technologies will transform healthcare positively [5].

Many healthcare professionals therefore expect that digital technologies and remote monitoring tools could help them to handle the growing patient data volumes they are currently feeling overwhelmed with [5]. 

The current recommendations for the psychiatric 10-year plan acknowledge that digital solutions can facilitate making better use of resources available in the future, and ensure the capacity meets the growing demand for mental health services. The use of digital technology offers the potential to address challenges in Danish mental health services. In particular, the use of digital platforms for remote patient monitoring and health assessment could improve access and speed to care, and real-time patient analytics could enable personalised treatment and improved quality of care [5]. 

Everyone deserves access to mental healthcare. The integration of digital solutions in healthcare bears huge potential, and it needs to happen timely. There is never a better time to act.
——————————————————————————————————————————-

About Monsenso
Monsenso is a digital health company that enables better outcomes for patients and clinicians through data-driven decisions. We are focused on mental health and user-centred in designing our solutions for patients and clinicians. At Monsenso, we focus on ensuring that the right service can be offered to the right patient at the right time by enabling stepped- and blended care. Our digital health solution can thus be a support to clinicians where resources are scarce and additionally ease healthcare professionals’ workload by providing them with a better overview of their patients’ data and conditions. The Monsenso solution also offers clinicians the possibility of early data collection for better diagnosis and treatment, as well as enabling early intervention by e.g., giving patients access to psychoeducation. Our cloud-based platform is a CE-marked medical device (Class 1, pending Class 2a and MDR certification) that is HIPAA compliant, with certifications in ISO 13485, ISO 27001, Cyber Essentials, and TGA. Our solution has been clinically and scientifically validated by over 70+ peer-reviewed studies and can be configured for applications across mental health conditions. We work with healthcare systems, life sciences, and research organisations globally. Book a demo to learn more.

References:

[1] EN AF OS (n.d.). About EN AF OS. Sundhedsstyrelsen.
http://www.en-af-os.dk/da/English/About-us#:~:text=Statistically%2C%201%20in%205%20Danes,they%20will%20get%20well%20again.

[2] Sundhedsstyrelsen (2022). Fagligt oplæg til en 10-årsplan.
https://www.sst.dk/da/Udgivelser/2022/Fagligt-oplaeg-til-en-10-aarsplan

[3] Kofoed (2022). Der er mangel på psykologer over hele landet – og det kan især gå ud over unge. DR.
https://www.dr.dk/nyheder/indland/der-er-mangel-paa-psykologer-over-hele-landet-og-det-kan-isaer-gaa-ud-over-unge

[4] Kofoed et al. (2022). Millioner til psykologhjælp forbliver ubrugte trods rekordlange ventetider. DR.
https://www.dr.dk/nyheder/politik/kommunalvalg/millioner-til-psykologhjaelp-forbliver-ubrugte-trods-rekordlange

[5] Elsevier Health (2022). Clinician of the Future Report 2022.
https://www.elsevier.com/connect/clinician-of-the-future

Monsenso expands to Israel as part of a real-world evidence project in pharma

Monsenso expands to Israel as part of a real-world evidence project in pharma

Monsenso is translating its digital health app to Hebrew and Russian as part of a real-world evidence project with a pharmaceutical customer in Israel.

Monsenso’s digital health solution is translated to Hebrew and Russian and will be implemented in Israel as part of a project, where it will be used to collect real-world patient-reported health data and data from connected wearables to support evidence generation for a specific drug.

With these recent additions, Monsenso’s digital health solution is now available in 19 countries and 12 languages.

The project is a great example of the relevance of Monsenso’s solution to help pharmaceuticals generate the evidence necessary to support regulatory approval and reimbursement dialogues. It helps pave the way to provide Monsenso’s solution internationally to customers wishing to collect valuable, longitudinal patient data via daily self-reports, periodic clinical questionnaires as well as sensor data from phones and connected wearables to support studies and clinical practice.

CEO Thomas Lethenborg says: “We are excited to continue our success in the pharmaceutical market and offer our digital health solution in more languages and countries going forward, thus enabling even more individuals globally to better take care of their mental health”.

——————————————————————————————————————————-
About Monsenso
Monsenso is a digital health company that enables better outcomes for patients and clinicians through data-driven decisions. We are focused on mental health and user-centred in designing our solutions for patients and clinicians. Our cloud-based platform is a CE-marked medical device (Class 1, pending Class 2a and MDR certification) that is HIPAA compliant, with certifications in ISO 13485, ISO 27001, Cyber Essentials, and TGA. Our solution has been clinically and scientifically validated by over 70+ peer-reviewed studies and can be configured for applications across mental health conditions. We work with healthcare systems, life sciences, and research organisations globally. Book a demo to learn more.

Monsenso will be working with Australian mental health clinic

Monsenso will be working with Australian mental health clinic

Monsenso will be working with the mental health clinic Aware Family Wellness in Australia.

Aware Family Wellness focuses on providing outpatient treatment to individuals in all age groups across a broad range of mental disorders, such as depression and perinatal depression, anxiety, eating disorders, complex trauma, and others.

Patients will be offered the Monsenso digital health solution as part of the treatment at the clinic, with the overall aim to better prepare patients for consultations, enhance the probability of correct and timely diagnosis and treatment, and thereby reduce the number of admissions and the probability of serious illness.

Founder and Accredited Mental Health Social Worker, Amy Ware says: “We are looking forward to using the Monsenso digital health solution to support our patients even more actively, and offering them a solution that provides them with self-help tools and psychoeducational material, enabling them to take better care of their mental health outside of treatment sessions”.

——————————————————————————————————————————-
About Monsenso
Monsenso is a digital health company that enables better outcomes for patients and clinicians through data-driven decisions. We are focused on mental health and user-centred in designing our solutions for patients and clinicians. Our cloud-based platform is a CE-marked medical device (Class 1, pending Class 2a and MDR certification) that is HIPAA compliant, with certifications in ISO 13485, ISO 27001, Cyber Essentials, and TGA. Our solution has been clinically and scientifically validated by over 70+ peer-reviewed studies and can be configured for applications across mental health conditions. We work with healthcare systems, life sciences, and research organisations globally. Book a demo to learn more.